Insulinoma clinical trials

The registry lists 62 studies for Insulinoma across more than 10 countries. 12 are recruiting or about to start. 16 of them are mainly about Insulinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-20.

Get an email when these change. Save the Insulinoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 27
Recruiting: 10
Terminated: 9
Status unknown: 6
Withdrawn: 5
Available: 2

Phase

Phase 2: 24
Phase 1: 13
Phase 3: 4
Early Phase 1: 3

Where

United States: 35
China: 10
United Kingdom: 4
Canada: 3
Netherlands: 2
Denmark: 2

Who runs them

National Cancer Institute (NCI) (8) · Peking Union Medical College Hospital (5) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · British Columbia Cancer Agency (3) · Rezolute (2) · Vanderbilt-Ingram Cancer Center (2) · Eastern Cooperative Oncology Group (2) · ECOG-ACRIN Cancer Research Group (2)

What is being tested here

Drugs under test in Insulinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Fluorodopa F 18	2	0	2
Ersodetug	1	1	1
Temozolomide	0	0	3
Everolimus	0	0	3
Capecitabine	0	0	3
Vatalanib	0	0	2
Bevacizumab	0	1	2
Octreotide	0	0	2
Motesanib diphosphate	0	0	1
Regorafenib	0	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 8 · Antimetabolites 5 · Alkylating agents 4

Coming up

1phase 3 study under way

3studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Sep 2027A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism · Phase 3 · Rezolute
Aug 2027Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization · Peking Union Medical College Hospital
Nov 2027Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease · Tianjin Medical University

Who these studies take

Of the 10 Insulinoma studies recruiting now, 3 (30%) set no upper age limit and 4 (40%) stop at 75 or younger. 4 (40%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (10%) take healthy volunteers.

Recruiting studies that take each age, of 10
Age	Women	Men
10	3 (30%)	3 (30%)
18	10 (100%)	10 (100%)
30	9 (90%)	9 (90%)
40	9 (90%)	9 (90%)
50	9 (90%)	9 (90%)
65	9 (90%)	9 (90%)
75	7 (70%)	7 (70%)
85	4 (40%)	4 (40%)

Across all 62 studies, recruiting or not: 13% stop at 75 or younger and 3% at 65; 19% take children; 0% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 62. Browse all 62 → or search them.